Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Incontinence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Erectile Dysfunction 1Carcinoma 1Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 49enzalutamide 46apalutamide 36Specimen Handling 34Androgen Antagonists 30Abiraterone Acetate 29Radiosurgery 27Prednisone 26darolutamide 25Docetaxel 23Pluvicto 22abiraterone 20Radiotherapy 19Biopsy 17Leuprolide 15relugolix 11gallium 68 PSMA-11 11acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11Surveys and Questionnaires 11Radiation 112-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 11Standard of Care 10Nivolumab 10cabazitaxel 9X-Rays 9Triptorelin Pamoate 9bicalutamide 8Carboplatin 8pembrolizumab 7olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Tadalafil × 90 days × Clear all
NCT07576335 2026-05-08

ROBOPREP

Surgical Outcomes Research Centre (SOuRCe)

Phase 2 Not yet recruiting
64 enrolled
Genitourinary

Erectile Dysfunction, Prostatic Neoplasms, Urinary Incontinence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡